Trial Profile
A phase III, single-blind, randomized comparative clinical trial of efficacy and safety of remimazolam versus propofol
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Remimazolam (Primary) ; Propofol
- Indications General anaesthesia
- Focus Registrational; Therapeutic Use
- Sponsors Hana Pharm
- 12 Aug 2020 According to a PAION media release, licensee Hana Pharm submitted a market approval dossier in general anesthesia in December 2019. Market approval is currently expected in 2020.
- 08 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to a PAION media release.
- 22 Mar 2018 Status changed from planning to recruiting,According to PAION media release